Recombinant vaccines are produced using recombinant DNA technology, with the help of a vector. These vaccines stimulate the immune system of an individual and provide immunity against various lethal disease. These vaccines are safe and have less or no side-effects as compared to conventional vaccines, in the prevention of various diseases such as influenza, cholera, typhoid, and dengue. Recombinant vaccines are also used in animals for prevention of diseases such as foot and mouth disease, pneumonia and septicemia, and pox disease. Vaccination results in the prevention of disease, by producing antibodies against the protein antigen of pathogenic microorganisms. There is increase in the demand for livestock products, which in turn has increased growth of the animal recombinant vaccine segment and Europe dominates the animal recombinant vaccines market as compared to other regions due to highly organized livestock and huge demand of livestock product for the European population. According to Global Agriculture report, there were around 315 million tons of meat produced worldwide in 2014 and expected to increase to 318.8 million tons in 2015.
The recent past has witnessed a steady rise in incidence of zoonotic and infectious diseases in humans and animals as well, which lead to the increased research & developments for the innovation of new and effective recombinant vaccines for the prevention of diseases. Government has also taken an initiative to increase awareness regarding vaccination to prevent diseases in community. Manufacturing companies have also started some beneficial programs to provide vaccination free of cost to poor people, which creates a highly conducive environment for growth of the recombinant vaccines market in near future.
National Immunization Program by Queensland Government in Australia and Indradhanush vaccination program in India works to provide vaccination among children throughout the nation. Various organizations such as World Health Organization, World Bank, and United Nations Children’s Funds has also taken and initiative to increase vaccination.
The global recombinant vaccine market was valued at US$ 830.2 million in 2016 and is expected to witness a robust CAGR of 6.0% during the forecast period (2017 – 2025).
Increase in the incidence of zoonotic diseases and emerging technologies expected to support the growth of recombinant vaccines market
There is a constant increase in diseases caused by bacteria or virus such as swine flu, malaria, HPV and other diseases, which has raised the demand of vaccination and lead to the eradication of diseases such as polio, and tetanus in few countries. Whit the development in technology there is development in vaccines, which are more effective than conventional vaccines and does not lead to any side effect. These vaccines are easy to administer in the body orally, intramuscular or intradermal. In the U.S. there were around 212 million malaria cases and 429,000 deaths from malaria is reported in 2015. According to Centers for Disease Control and Prevention report 2017, in the U.S. there were around 49.9% of the children between the ages of 6 months to 17 years received an influenza vaccine.
Continuous investment in research & development for the development of new vaccines and increased awareness and pet adoption are expected to fuel the growth of recombinant vaccines
There are various companies working on the development of vaccine for various disease, which have affected human beings in short span of time such as Ebola, Zika, and H1N1 flu. The companies also working for the development of cancer vaccines different type of cancer includes lung cancer, blood cancer, skin cancer, bladder cancer, brain cancer, kidney cancer, prostate cancer, solid tumors cancer , breast cancer are the target area for recombinant vaccine development, which may expected to support the growth of recombinant vaccine market in the near future. In 2012, according to the World Cancer Research Fund International, globally around 1.7 million new cases of breast cancer are diagnosed. Breast cancers are being targeted in active NCI supported cancer prevention or treatment clinical trials using vaccines.
Some major key players in the recombinant vaccines market include Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi S A, Pfizer Inc., and Bharat Biotech.